# Learning from UK Biobank by following AstraZeneca's footsteps

 ![multi-omics](./multi-omics.png)

## Genomics

 Variant-level associations and Gene-level associations(Collapsing analysis):
 
 **AstraZeneca PheWAS Portal:** https://azphewas.com

 [Wang Q, Dhindsa R S, Carss K, et al. Rare variant contribution to human disease in 281,104 UK Biobank exomes[J]. Nature, 2021, 597(7877): 527-532.](https://www.nature.com/articles/s41586-021-03855-y)

 [Nag A, Dhindsa R S, Mitchell J, et al. Human genetics uncovers MAP3K15 as an obesity-independent therapeutic target for diabetes[J]. Science advances, 2022, 8(46): eadd5430.](https://www.science.org/doi/full/10.1126/sciadv.add5430)

## Transcriptomics

 []

## Proteomics

  **pQTL interactions from UKB-PPP**:https://astrazeneca-cgr-publications.github.io/pqtl-browser/

 [Dhindsa R S, Burren O S, Sun B B, et al. Rare variant associations with plasma protein levels in the UK Biobank[J]. Nature, 2023, 622(7982): 339-347.](https://www.nature.com/articles/s41586-023-06547-x)

## Metabolomics

 [Nag A, Dhindsa R S, Middleton L, et al. Effects of protein-coding variants on blood metabolite measurements and clinical biomarkers in the UK Biobank[J]. The American Journal of Human Genetics, 2023, 110(3): 487-498.](https://www.cell.com/ajhg/fulltext/S0002-9297(23)00046-0)